SCNX Share Price Performance
US$1.94
-4.90 (-71.64%)
Price US$1.94
Share PriceUS$1.94
SCNX Community Narratives
There are no narratives available yet.
Recent SCNX News & Updates
No updates
Scienture Holdings, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.91
- Gross Margin
- 4.55%
- Net Profit Margin
- -9,989.76%
- Debt/Equity Ratio
- 4.4%
Scienture Holdings, Inc. Competitors
About SCNX
- Founded
- n/a
- Employees
- 17
- CEO
- WebsiteView website
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is based in Tampa, Florida.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 11.4%
- 1 Year: 20.5%
- Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a decline of 2.4% in the Information Technology sector. As for the longer term, the market has actually risen by 20% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading